← Russell 3000 cross-section

CUE Cue Biopharma, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-14, not restated
Healthcare

Scale

Market cap
$200m
Revenue TTM
$38m
Net income TTM
$-164m
Free cash flow
$-50m
Composite score
Sector rank
#2874

Valuation

P / E
EV / EBITDA
EV / sales
4.8
FCF yield
-25.09%
Earnings yield vs 10-yr
-86.81pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-435.8%
EBITDA margin
-261.4%
ROE
-7,104.2%
ROIC
Revenue growth
354.4%

Insider activity, last 90 days

Net open-market
$-2.04m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Under the Einstein License, we are required to: • Pay royalties and amounts based on a certain percentage of proceeds, as defined in the Einstein License, from sales of Einstein Licensed Products and sublicense agreements. • Pay escalating annual maintenance fees, which are non-refundable, but are creditable against the amount due to Einstein for royalties. • Make significant payments based upon the achievement of certain milestones, as defined in the Einstein License. As of June 30, 2026, we had recorded $14.8 million in collaboration revenue related to this agreement since the agreement was entered into. …Cue Biopharma, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-14

Read the full passage →